Biotech Catalysts This Week: FDA Decisions, Readouts & Earnings (Jul 19–Jul 26, 2026)

· 1 min read

Here’s what’s on the biotech calendar for July 19–July 26: 0 FDA decision dates, 2 trial catalysts, and 0 earnings reports from tracked companies.

🧪 Trial Catalysts & Milestones

  • OSTX — 2026-07-21: CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL
  • OSTX — 2026-07-24: Immune Metabolism Dysregulation and Efficacy to Anti-PD-1 PD-L1 Agents in Non Small Cell L

📡 Run-up Radar Highlights

Stocks entering the pre-catalyst window with the strongest setups (full radar is a Premium feature):

  • CORT — Phase 2 — Recruiting in 13 days, score 68/100
  • ACIU — Phase 1 — Recruiting in 13 days, score 61/100
  • CADL — Phase 2 — Recruiting in 13 days, score 60/100

📈 Last Week’s Biggest Gainers

  • CDNA +35.60% (volume 5.5x average)
  • ATAI +33.40% (volume 21.4x average)
  • MAN +32.37% (volume 4.5x average)
  • LCID +28.79% (volume 2.9x average)
  • CHRN +28.77% (volume 2.6x average)

Track your tickers on the BioRadar dashboard →

This digest is for informational purposes only and is not investment advice. Always do your own research.

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.